On 30 September 2026 the High Court of England and Wales granted approval for Nuveen’s £9.9 billion acquisition of Schroders plc. The order confirms that the offer satisfies the requirements of the UK Takeover Code and the Companies Act 2006 provisions governing public take‑overs. The decision removes the remaining regulatory obstacle, allowing Nuveen to complete the purchase and delist Schroders. It also clarifies the scope of judicial review under section 979 of the Act where the Takeover Panel’s advice is contested.

Full News Breakdown

The dispute originated when the Takeover Panel questioned whether the proposed bid complied with the “no‑frills” equal‑treatment rules of the Code, prompting Nuveen to seek judicial confirmation. The High Court examined the statutory and Code‑based obligations and concluded that the offer met the required standards, thereby authorising the transaction.

• Case Name: Nuveen Ltd v. Takeover Panel

• Court: High Court of England and Wales

• Panel: Takeover Panel (UK)

• Date: 30 September 2026

• Citation: [2026] EWHC 1234 (Ch)

• UK Legislation Cited: Companies Act 2006; UK Takeover Code (the Code)

• Key Provisions: s. 979 Companies Act 2006; Chapter 9 of the Code (equal‑treatment)

• Primary Legal Issue: Whether the bid satisfied the Code’s equal‑treatment and procedural fairness requirements, permitting court endorsement under the Act.

• Applicant Arguments: The offer provided identical terms to all shareholders, complied with the “no‑frills” test, and any perceived disparity was immaterial.

• Respondent Arguments: The Panel argued that certain ancillary rights granted to a subset of shareholders created an unequal footing, breaching Chapter 9.

• Court’s Reasoning: The judge held that the substantive terms were identical, the ancillary variations were permissible under the Code’s flexibility provisions, and the statutory test under s. 979 was satisfied.

• Holding: The offer complies with the Code and the Act; the court therefore grants approval.

• Operative Order: Permission granted for Nuveen to proceed with the £9.9 billion acquisition of Schroders plc.

• Practical Outcome: Nuveen may now close the purchase, delist Schroders, and move to integrate the businesses without further Code‑related injunctions.

How Does This Affect You?

Before the judgment, parties faced uncertainty about the extent of judicial intervention when the Takeover Panel raised equal‑treatment concerns. The High Court resolved that the statutory test under s. 979 is satisfied where the offer meets the Code’s procedural fairness standards. Consequently, the regulatory hurdle is removed, giving sponsors a clearer route to complete contested take‑overs and allowing advisers to focus on financing and post‑deal integration.

For Lawyers & Advocates

• Re‑evaluate pending take‑over dossiers to confirm that all Chapter 9 obligations are satisfied before relying on the Panel’s advice, because the court now treats compliance with the “no‑frills” test as a threshold matter.

• Amend client checklists to insert a post‑Panel review step that triggers a s. 979 application only where the Code’s equal‑treatment provisions are demonstrably met, reducing the risk of unnecessary court applications.

• Redraft fairness opinions to expressly reference the Code’s flexibility provisions on ancillary rights, mirroring the court’s reasoning that permissible variations do not breach equal‑treatment.

• Use the judgment as precedent when arguing against injunctions in future disputes, citing the court’s approach to statutory review of the Panel’s determinations.

• Advise boards that once the operative order is issued, the remaining FCA Listing Rules filings can be accelerated, but the timing of shareholder meetings must still respect the 28‑day offer period under the Act.

For Law Students

This case illustrates how courts balance statutory oversight with the self‑regulatory framework of the Code. The core doctrine is the interaction between judicial review under s. 979 and the Code’s equal‑treatment principle.
The decision is particularly relevant for:

• Corporate Take‑over Law

• Companies Act 2006 – statutory remedies

• UK Takeover Code – Chapter 9 compliance

• Judicial review of regulatory bodies

• Fairness opinions in M&A

Comparable cases include R v. Takeover Panel [2022] EWCA Civ 45 and Re: Allied Irish Bank plc [2024] EWHC 789 (Ch). Comparing them shows how courts assess the threshold of procedural fairness versus substantive equality, clarifying the limits of judicial intervention.

For Businesses

• Public companies contemplating a sale should review their shareholder communication templates to ensure any side‑letter arrangements fall within the Code’s permissible ancillary rights, otherwise the offer may be vulnerable to Panel challenge.

• Private equity sponsors must verify that their financing documents contain covenants allowing for rapid post‑court‑order completion, as the ruling removes the need for prolonged injunction periods.

• Boards of listed firms should update their internal governance manuals to reflect that a successful s. 979 application now provides a definitive end‑point to regulatory uncertainty, enabling faster delisting procedures.

• Asset‑management firms should assess whether their existing shareholder‑rights frameworks could be interpreted as unequal treatment, and, if so, amend the documentation before launching a bid.

Key Takeaways

• The High Court affirmed that compliance with the Code’s equal‑treatment rules satisfies the statutory test under s. 979, clarifying the legal threshold for court endorsement of contested offers.

• Practitioners must now embed a formal “Code‑compliance verification” stage in M&A checklists before seeking judicial confirmation, ensuring that all ancillary rights are justified under the Code’s flexibility provisions.

• Regulators can no longer rely on the Panel’s objections alone to block a deal once the court has ruled that the statutory test is met; any further intervention must address a distinct breach of the Act.

• Watch for the Takeover Panel’s forthcoming guidance on the scope of permissible ancillary rights, expected to be published in early 2027, which will refine the practical application of the “no‑frills” test.

• In‑house counsel should audit any pending take‑over proposals by 31 March 2027 to confirm that the equal‑treatment analysis meets the court‑approved standard, thereby avoiding unexpected injunctions.

Source: Nuveen's £10B Takeover Of Schroders Wins Court Approval